Meropenem Qilu

Meropenem, the active ingredient in Meropenem Qilu, is a carbapenem antibiotic presented as a strength/form for intravenous use. It treats serious bacterial infections in hospitalized patients, including intra‑abdominal infections, pneumonia, and sepsis.

GNH USA supplies Meropenem Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for severe bacterial infections.

- Complicated intra‑abdominal infections: provides bactericidal activity against mixed aerobic and anaerobic pathogens. - Complicated urinary tract infections: eradicates resistant Gram‑negative organisms. - Hospital‑acquired pneumonia: treats multidrug‑resistant strains causing lower respiratory infection. - Severe sepsis and septic shock: offers rapid bacterial clearance in critical care. - Meningitis: penetrates the cerebrospinal fluid to eliminate causative bacteria.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limited. - Rash: erythematous skin eruption. - Headache: transient discomfort. - Elevated liver enzymes: mild transaminase increase. - Injection site phlebitis: local irritation at IV site.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or CNS disease. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption. - Anaphylaxis: acute, potentially life‑threatening allergic reaction. - Severe neutropenia: marked reduction in white blood cells. - Renal toxicity: acute kidney injury in susceptible individuals. - Hypersensitivity reactions: including Stevens‑Johnson syndrome.

Key safety considerations should be observed before and during therapy.

- Renal impairment: adjust dose based on creatinine clearance. - Hypersensitivity: avoid in patients with known carbapenem allergy. - Pregnancy: use only if benefit outweighs potential risk. - Liver function: monitor transaminases during prolonged treatment. - Concomitant valproic acid: increased risk of seizures; consider alternative. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug‑drug interactions require assessment.

Major Interactions (Avoid): - Valproic acid: may lower seizure threshold when combined with meropenem. - Other carbapenems: competitive inhibition may reduce efficacy. - Probenecid: decreases renal excretion, increasing meropenem levels.

Moderate Interactions (Monitor Closely): - Aminoglycosides: additive nephrotoxicity; monitor renal function. - Loop diuretics: may enhance renal clearance, affecting exposure. - Warfarin: possible INR fluctuations; check coagulation parameters. - Oral contraceptives: reduced effectiveness; advise alternative contraception. - NSAIDs: increased risk of renal impairment; observe kidney function.